NASDAQ$CRBP
Corbus Pharmaceuticals Holding · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended September 30, 2024.
Corbus Pharmaceuticals reported a net loss of $13.8 million, or $1.15 per diluted share, for the three months ended September 30, 2024. As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations through Q3 2027.
- Completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 in the U.S. and Europe, with first data expected in Q1 2025.
- Presented new pre-clinical data for CRB-913 at Obesity Week 2024, with Phase 1 trial expected to commence in Q1 2025.
- Expects to dose the first patient in Q4 2024 for the Phase 1 portion of the CRB-601 clinical study.
- The company had $159.4 million in cash, cash equivalents and investments on hand as of September 30, 2024.
Headline financials
Revenue & EPS history
Corbus Pharmaceuticals · Revenue · Quarterly
$10K
Forward guidance
The Company expects to report the first data from the CRB-701 U.S. bridging study in Q1 2025. The Company continues to conduct IND-enabling studies on CRB-913 and expects to dose the first patient in a Phase 1 study in Q1 2025. The Company expects to dose the first patient in Q4 2024 for the Phase 1 portion of the CRB-601 clinical study
Tailwinds
- First data from the CRB-701 U.S. bridging study is expected in Q1 2025.
- Emerging efficacy and safety data presented at ASCO 2024 was promising and demonstrated the drug is clinically active with a differentiated safety profile.
- Expected to dose the first patient in a Phase 1 study of CRB-913 in Q1 2025.
- CRB-601: The Company expects to dose the first patient in Q4 2024 for the Phase 1 portion of the CRB-601 clinical study
- As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations through Q3 2027
Headwinds
- Reported a net loss of approximately $13.8 million for the three months ended September 30, 2024.
- Operating expenses increased by $6.0 million to approximately $15.5 million for the three months ended September 30, 2024
- Increase was primarily attributable to an increase of $3.2 million in CRB-701 clinical trial costs with our contract research organization ("CRO") and clinical sites
- IND-enabling studies for CRB-913 of $1.0 million
- Higher compensation costs of $1.6 million mainly due to stock-based compensation expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-1.6%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+8.6%
Avg return
30 days after
30%
14 / 46 earnings
Positive
+23.0%
Q4 2023
Best reaction
-24.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.0% | +0.1% | -29.3% | |
| Q4 2025 | +18.6% | +17.5% | +22.8% | |
| Q3 2025 | +6.5% | +8.0% | -6.9% | |
| Q1 2025 | -16.3% | -13.1% | +18.6% | |
| Q4 2024 | -9.1% | -17.4% | -13.4% | |
| Q3 2024 | -0.7% | -5.1% | -19.3% | |
| Q2 2024 | -12.2% | +2.8% | -7.7% | |
| Q1 2024 | +9.2% | +10.7% | +20.0% | |
| Q4 2023 | +23.0% | +14.1% | +4.5% | |
| Q3 2023 | -24.2% | -35.5% | +7.1% | |
| Q2 2023 | -4.7% | +3.9% | +9.5% | |
| Q1 2023 | -8.1% | -2.9% | -8.0% | |
| Q4 2022 | -11.6% | -24.9% | +171.9% | |
| Q3 2022 | -3.8% | +1.5% | -0.8% | |
| Q2 2022 | -4.5% | -3.7% | -25.5% | |
| Q1 2022 | -10.6% | -19.2% | +12.5% | |
| Q4 2021 | +15.4% | +25.5% | +32.7% | |
| Q3 2021 | +5.7% | -3.8% | -28.8% | |
| Q2 2021 | -6.8% | -7.5% | -10.5% | |
| Q1 2021 | +12.1% | +9.4% | +46.3% | |
| Q4 2020 | -6.4% | +0.9% | -25.3% | |
| Q3 2020 | +0.0% | +4.9% | +8.2% | |
| Q2 2020 | -7.6% | -2.7% | +29.4% | |
| Q1 2020 | +3.3% | +4.3% | +11.0% | |
| Q4 2019 | -1.2% | +2.2% | +39.6% | |
| Q3 2019 | -6.4% | -11.0% | +4.7% | |
| Q2 2019 | +3.2% | +7.0% | -4.4% | |
| Q1 2019 | -0.8% | -4.9% | -9.9% | |
| Q4 2018 | +8.1% | +11.1% | +17.1% | |
| Q3 2018 | -13.3% | -16.5% | -9.4% | |
| Q2 2018 | +0.0% | +2.6% | +12.5% | |
| Q1 2018 | -14.5% | -1.6% | -10.2% | |
| Q4 2017 | -4.9% | +0.0% | -12.7% | |
| Q3 2017 | +2.9% | +0.0% | +10.2% | |
| Q2 2017 | -4.1% | -0.8% | +10.7% | |
| Q1 2017 | -4.0% | +1.6% | +2.4% | |
| Q4 2016 | +1.6% | +4.4% | -20.9% | |
| Q3 2016 | -9.3% | +26.4% | +20.9% | |
| Q2 2016 | -1.0% | +5.5% | +67.2% | |
| Q1 2016 | -2.5% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | -6.1% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -0.5% | — | — | |
| Q3 2014 | +16.7% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro